No Data
Wall Street Today: Market Ends Wild Political TV Day in the Green
Boehringer Ingelheim and Eisai stated that European Institutions reaffirm support for Alzheimer’s disease medications.
On Friday, Biogen and Eisai announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has reiterated its recommendation to approve their Alzheimer's drug Leqembi (lecanemab). The two companies stated on Friday that the European Commission had asked the committee to consider safety information regarding Leqembi obtained after a positive opinion was issued in November, and the European Commission will resume its decision-making process for the drug's marketing authorization. The committee requested the Committee for Medicinal Products for Human Use to consider new information last month.
Biogen, Eisai Alzheimer's Drug Sent Back for EU Nod After Safety Review
The CHMP Reaffirms Positive Opinion For Lecanemab In Early Alzheimer's Disease
Express News | EMA Says Chmp: Concluded That Its Opinion Recommending Marketing Authorisation for Leqembi (Lecanemab) Does Not Need to Be Updated
Wall Street Today: Market Decides Down is the Direction
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
72886030 : any thoughts why it is dropping after the earnings?
thoughtful Bat_8163 OP 72886030 : forecast? To be honest, it is really disappointing regarding Leqembi rollout. BIIB has betted huge on it. I was expecting much better quarter over quarter growth
72886030 thoughtful Bat_8163 OP : thanks for sharing. hope all the bad news are priced in now.